Retroviral vectors for gene therapy

Future Microbiology

Volumn 5, Issue 10, 2010, Pages 1507-1523

  Maier, Patrick ^a   Von Kalle, Christof ^b   Laufs, Stephanie ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

gene therapy; improved vector design; insertional mutagenesis; lentiviral vectors; retroviral vectors

Indexed keywords

ADENOSINE DEAMINASE; ADENOVIRUS VECTOR; COMPLEMENTARY DNA; LENTIVIRUS VECTOR; MICRORNA; PARVOVIRUS VECTOR; RETROVIRUS VECTOR;

CLINICAL TRIAL; GENE THERAPY; GENE TRANSFER; HUMAN; INTERNAL RIBOSOME ENTRY SITE; LIFE CYCLE; LONG TERMINAL REPEAT; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PSEUDOTYPING; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; TRANSGENE;

GENE THERAPY; GENETIC VECTORS; HUMANS; RETROVIRIDAE;

EID: 78449235081     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.100     Document Type: Review

References (172)

1. Cockrell AS, Kafri T: Gene delivery by lentivirus vectors. Mol. Biotechnol. 36(3), 184-204 (2007).
2. Mulligan RC: The basic science of gene therapy. Science 260(5110), 926-932 (1993).
3. Flotte TR: Gene therapy: the frst two decades and the current state-of-the-art. J. Cell Physiol. 213(2), 301-305 (2007).
4. Davis ME: Non-viral gene delivery systems. Curr. Opin. Biotechnol. 13(2), 128-131 (2002).
5. Wells DJ: Electroporation and ultrasound enhanced non-viral gene delivery in vitro and in vivo. Cell Biol. Toxicol. 26(1), 21-28 (2009).
6. Qian C, Prieto J: Gene therapy of cancer: induction of anti-tumor immunity Cell Mol. Immunol. 1(2), 105-111 (2004).
7. Lechardeur D, Lukacs GL: Intracellular barriers to non-viral gene transfer. Curr. Gene Ther. 2(2), 183-194 (2002).
8. Wolff JA, Budker V: The mechanism of naked DNA uptake and expression. Adv. Genet. 54, 3-20 (2005).
9. Kootstra NA, Verma IM: Gene therapy with viral vectors. Annu. Rev. Pharmacol. Toxicol. 43, 413-439 (2003).
10. Retroviruses. Coffn JM, Hughes SH, Varmus He (Eds). Cold Spring Harbor Laboratory Press (1999).
11. Goff SP: Genetics of retroviral integration. Annu. Rev. Genet. 26, 527-544 (1992).
12. Andersen KB, Skov H: Retrovirus-induced cell fusion is enhanced by protease treatment. J. Gen. Virol. 70(Pt 7), 1921-1927 (1989).
13. Abbotts J, Bebenek K, Kunkel TA, Wilson SH: Mechanism of HIV-1 reverse transcriptase. Termination of processive synthesis on a natural DNA template is infuenced by the sequence of the template-primer stem. J. Biol. Chem. 268(14), 10312-10323 (1993).
14. Hu WS, Pathak VK: Design of retroviral vectors and helper cells for gene therapy Pharmacol. Rev. 52(4), 493-511 (2000).
15. Naldini L: Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr. Opin. Biotechnol. 9(5), 457-463 (1998).
16. Bowerman B, Brown PO, Bishop JM, Varmus HE: A nucleoprotein complex mediates the integration of retroviral DNA. Genes Dev. 3(4), 469-478 (1989).
17. Brown PO, Bowerman B, Varmus HE, Bishop JM: Retroviral integration: structure of the initial covalent product and its precursor, and a role for the viral in protein. Proc. Natl Acad. Sci. USA 86(8), 2525-2529 (1989).
18. Allen P, Worland S, Gold L: Isolation of high-affnity RNA ligands to HIV-1 integrase from a random pool. Virology 209(2), 327-336 (1995).
19. Trobridge GD: Foamy virus vectors for gene transfer. Expert Opin. Biol. Ther. 9(11), 1427-1436 (2009).
20. Miller AD, Rosman GJ: Improved retroviral vectors for gene transfer and expression. Biotechniques 7(9), 980-982, 984-986, 989-990 (1989).
21. Markowitz D, Goff S, Bank A: Construction and use of a safe and effcient amphotropic packaging cell line. Virology 167(2), 400-406 (1988).
22. Miller AD, Garcia JV, Von Suhr N, Lynch CM, Wilson C, Eiden MV: Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J. Virol. 65(5), 2220-2224 (1991).
23. Danos O, Mulligan RC: Safe and effcient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl Acad. Sci. USA 85(17), 6460-6464 (1988).
24. Sanders DA: No false start for novel pseudotyped vectors. Curr. Opin. Biotechnol. 13(5), 437-442 (2002).
25. Beyer WR, Westphal M, Ostertag W, Von Laer D: Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J. Virol. 76(3), 1488-1495 (2002).
26. Hsu M, Zhang J, Flint M et al.: Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl Acad. Sci. USA 100(12), 7271-7276 (2003).
27. Kolokoltsov AA, Weaver SC, Davey RA: Effcient functional pseudotyping of oncoretroviral and lentiviral vectors by venezuelan equine encephalitis virus envelope proteins. J. Virol. 79(2), 756-763 (2005).
28. Sung VM, Lai MM: Murine retroviral pseudotype virus containing hepatitis B virus large and small surface antigens confers specifc tropism for primary human hepatocytes: a potential liver-specifc targeting system. J. Virol. 76(2), 912-917 (2002).
29. Lewis PF, Emerman M: Passage through mitosis is required for oncoretroviruses but not for the human immunodefciency virus. J. Virol. 68(1), 510-516 (1994).
30. Miller DG, Adam MA, Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell Biol. 10(8), 4239-4242 (1990).
31. Scherr M, Battmer K, Eder M et al.: Effcient gene transfer into the CNS by lentiviral vectors purifed by anion exchange chromatography. Gene Ther. 9(24), 1708-1714 (2002).
32. Fouchier RA, Malim MH: Nuclear import of human immunodefciency virus type-1 preintegration complexes. Adv. Virus Res. 52, 275-299 (1999).
33. Naldini L, Blomer U, Gage FH, Trono D, Verma IM: Effcient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl Acad. Sci. USA 93(21), 11382-11388 (1996).
34. Whittaker GR, Kann M, Helenius A: Viral entry into the nucleus. Annu. Rev. Cell Dev. Biol. 16, 627-651 (2000).
35. Barraza RA, Poeschla EM: Human gene therapy vectors derived from feline lentiviruses. Vet. Immunol. Immunopathol. 123(1-2), 23-31 (2008).
36. Poeschla EM: Non-primate lentiviral vectors. Curr. Opin. Mol. Ther. 5(5), 529-540 (2003).
37. Mselli-Lakhal L, Favier C, Da Silva Teixeira MF et al.: Defective RNA packaging is responsible for low transduction effciency of CAEV-based vectors. Arch. Virol. 143(4), 681-695 (1998).
38. Berkowitz R, Ilves H, Lin WY et al.: Construction and molecular analysis of gene transfer systems derived from bovine immunodefciency virus. J. Virol. 75(7), 3371-3382 (2001). (Pubitemid 32225900)
39. Berkowitz RD, Ilves H, Plavec I, Veres G: Gene transfer systems derived from visna virus: analysis of virus production and infectivity. Virology 279(1), 116-129 (2001). (Pubitemid 34162554)
40. Kumar M, Keller B, Makalou N, Sutton RE: Systematic determination of the packaging limit of lentiviral vectors. Hum. Gene Ther. 12(15), 1893-1905 (2001).
41. Ikeda Y, Takeuchi Y, Martin F, Cosset FL, Mitrophanous K, Collins M: Continuous high-titer HIV-1 vector production. Nat. Biotechnol. 21(5), 569-572 (2003).
42. Xu K, Ma H, Mccown TJ, Verma IM, Kafri T: Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol. Ther. 3(1), 97-104 (2001).
43. Cockrell AS, Ma H, Fu K, Mccown TJ, Kafri T: A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol. Ther. 14(2), 276-284 (2006).
44. Throm RE, Ouma AA, Zhou S et al.: Effcient construction of producer cell lines for a sin lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 113(21), 5104-5110 (2009).
45. Broussau S, Jabbour N, Lachapelle G et al.: Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol. Ther. 16(3), 500-507 (2008).
46. Segura MM, Garnier A, Durocher Y, Coelho H, Kamen A: Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affnity chromatography purifcation. Biotechnol. Bioeng. 98(4), 789-799 (2007).
47. Segura MM, Kamen A, Garnier A: Downstream processing of oncoretroviral and lentiviral gene therapy vectors. Biotechnol. Adv. 24(3), 321-337 (2006).
48. Cullen BR: Regulation of human immunodefciency virus replication. Annu. Rev. Microbiol. 45, 219-250 (1991).
49. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D: Multiply attenuated lentiviral vector achieves effcient gene delivery in vivo. Nat. Biotechnol. 15(9), 871-875 (1997).
50. Kang Y, Stein CS, Heth JA et al.: In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross river virus glycoproteins. J. Virol. 76(18), 9378-9388 (2002).
51. Kumar M, Bradow BP, Zimmerberg J: Large-scale production of pseudotyped lentiviral vectors using baculovirus gp64. Hum. Gene Ther. 14(1), 67-77 (2003).
52. Sena-Esteves M, Tebbets JC, Steffens S, Crombleholme T, Flake AW: Optimized large-scale production of high titer lentivirus vector pseudotypes. J. Virol. Methods 122(2), 131-139 (2004).
53. Sinn PL, Hickey MA, Staber PD et al.: Lentivirus vectors pseudotyped with floviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor a. J. Virol. 77(10), 5902-5910 (2003).
54. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK: Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and effcient gene transfer into mammalian and nonmammalian cells. Proc. Natl Acad. Sci. USA 90(17), 8033-8037 (1993).
55. Lindemann D, Bock M, Schweizer M, Rethwilm A: Effcient pseudotyping of murine leukemia virus particles with chimeric human foamy virus envelope proteins. J. Virol. 71(6), 4815-4820 (1997).
56. Stitz J, Buchholz CJ, Engelstadter M et al.: Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10a1. Virology 273(1), 16-20 (2000).
57. + cells derived from human and nonhuman primates. Blood 100(3), 823-832 (2002).
58. Funke S, Maisner A, Muhlebach MD et al.: Targeted cell entry of lentiviral vectors. Mo l. Ther. 16(8), 1427-1436 (2008).
59. Sinn PL, Penisten AK, Burnight ER et al.: Gene transfer to respiratory epithelia with lentivirus pseudotyped with Jaagsiekte sheep retrovirus envelope glycoprotein. Hum. Gene Ther. 16(4), 479-488 (2005).
60. Connolly JB: Lentiviruses in gene therapy clinical research. Gene Ther. 9(24), 1730-1734 (2002).
61. Demaison C, Parsley K, Brouns G et al.: High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodefciency [correction of imunodefciency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum. Gene Ther. 13(7), 803-813 (2002).
62. Rubinson DA, Dillon CP, Kwiatkowski AV et al.: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. 33(3), 401-406 (2003).
63. Jenkins NA, Copeland NG, Taylor BA, Lee BK: Dilute (d) coat colour mutation of DBA/2J mice is associated with the site of integration of an ecotropic MuLV genome. Nature 293 (5831), 370-374 (1981).
64. Noori-Daloii MR, Swift RA, Kung HJ, Crittenden LB, Witter RL: Specifc integration of rev proviruses in avian bursal lymphomas. Nature 294(5841), 574-576 (1981).
65. Payne GS, Courtneidge SA, Crittenden LB, Fadly AM, Bishop JM, Varmus HE: Analysis of avian leukosis virus DNA and RNA in bursal tumours: viral gene expression is not required for maintenance of the tumor state. Cell 23(2), 311-322 (1981).
66. Varmus HE, Quintrell N, Ortiz S: Retroviruses as mutagens: insertion and excision of a nontransforming provirus alter expression of a resident transforming provirus. Cell 25(1), 23-36 (1981).
67. Zufferey R, Dull T, Mandel RJ et al.: Self-inactivating lentivirus vector for safe and effcient in vivo gene delivery. J. Virol. 72(12), 9873-9880 (1998).
68. Modlich U, Bohne J, Schmidt M et al.: Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108(8), 2545-2553 (2006).
69. Kim DW, Uetsuki T, Kaziro Y, Yamaguchi N, Sugano S: Use of the human elongation factor 1 a promoter as a versatile and effcient expression system. Gene 91(2), 217-223 (1990).
70. Dull T, Zufferey R, Kelly M et al.: A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72(11), 8463-8471 (1998).
71. Logan AC, Nightingale SJ, Haas DL, Cho GJ, Pepper KA, Kohn DB: Factors infuencing the titer and infectivity of lentiviral vectors. Hum. Gene Ther. 15(10), 976-988 (2004).
72. Brun S, Faucon-Biguet N, Mallet J: Optimization of transgene expression at the posttranscriptional level in neural cells: implications for gene therapy. Mol. Ther. 7(6), 782-789 (2003).
73. Zufferey R, Donello JE, Trono D, Hope TJ: Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73(4), 2886-2892 (1999).
74. -human hematopoietic cells by HIV-1-based lentiviral vectors. Proc. Natl Acad. Sci. USA 96(6), 2988-2993 (1999).
75. + cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 283(5402), 682-686 (1999).
76. + NOD/SCID-repopulating cells. Blood 99(2), 709-712 (2002).
77. Miller AD, Miller DG, Garcia JV, Lynch CM: Use of retroviral vectors for gene transfer and expression. Methods Enzymol. 217, 581-599 (1993).
78. 6-methylguanine-DNA methyltransferase(p140k). Gene Ther. 17(3), 389-399 (2009).
79. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fbroblast cultures by defned factors. Cell 126(4), 663-676 (2006).
80. McLachlin JR, Mittereder N, Daucher MB, Kadan M, Eglitis MA: Factors affecting retroviral vector function and structural integrity. Virology 195(1), 1-5 (1993).
81. Emerman M, Temin HM: Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 39(3 Pt 2), 449-467 (1984).
82. Emerman M, Temin HM: Quantitative analysis of gene suppression in integrated retrovirus vectors. Mol. Cell Biol. 6(3), 792-800 (1986).
83. Bowtell DD, Cory S, Johnson GR, Gonda TJ: Comparison of expression in hemopoietic cells by retroviral vectors carrying two genes. J. Virol. 62(7), 2464-2473 (1988).
84. Cepko CL, Roberts BE, Mulligan RC: Construction and applications of a highly transmissible murine retrovirus shuttle vector. Cell 37(3), 1053-1062 (1984).
85. Jackson RJ, Kaminski A: Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond. RNA 1(10), 985-1000 (1995).
86. Pelletier J, Sonenberg N: Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 334(6180), 320-325 (1988).
87. Pelletier J, Sonenberg N: Internal binding of eucaryotic ribosomes on poliovirus RNA: translation in HeLa cell extracts. J. Virol. 63(1), 441-444 (1989).
88. Mountford PS, Smith AG: Internal ribosome entry sites and dicistronic rnas in mammalian transgenesis. Trends Genet. 11(5), 179-184 (1995).
89. Laufs S, Kim SH, Kim S, Blau N, Thony B: Reconstitution of a metabolic pathway with triple-cistronic IRES-containing retroviral vectors for correction of tetrahydrobiopterin defciency. J. Gene Med. 2(1), 22-31 (2000).
90. Pfutzner W: Retroviral bicistronic vectors. Drug News Perspect. 21(9), 473-480 (2008).
91. Marktel S, Magnani Z, Ciceri F et al.: Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 101(4), 1290-1298 (2003).
92. Wong ET, Ngoi SM, Lee CG: Improved co-expression of multiple genes in vectors containing internal ribosome entry sites (IRESes) from human genes. Gene Ther. 9(5), 337-344 (2002).
93. Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T: IRES-dependent second gene expression is signifcantly lower than cap-dependent frst gene expression in a bicistronic vector. Mol. Ther. 1(4), 376-382 (2000).
94. Borman AM, Le Mercier P, Girard M, Kean KM: Comparison of picornaviral IRES-driven internal initiation of translation in cultured cells of different origins. Nucleic Acids Res. 25(5), 925-932 (1997).
95. Szymczak AL, Vignali DA: Development of 2a peptide-based strategies in the design of multicistronic vectors. Expert Opin. Biol. Ther. 5(5), 627-638 (2005).
96. Donnelly ML, Gani D, Flint M, Monaghan S, Ryan MD: The cleavage activities of aphthovirus and cardiovirus 2a proteins. J. Gen. Virol. 78(Pt 1), 13-21 (1997).
97. Ryan MD, Drew J: Foot-and-mouth disease virus 2a oligopeptide mediated cleavage of an artifcial polyprotein. EMBO J. 13(4), 928-933 (1994).
98. Ryan MD, King AM, Thomas GP: Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J. Gen. Virol. 72(Pt 11), 2727-2732 (1991).
99. Donnelly ML, Hughes LE, Luke G et al.: The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. J. Gen. Virol. 82(Pt 5), 1027-1041 (2001).
100. De Felipe P, Hughes LE, Ryan MD, Brown JD: Co-translational, intraribosomal cleavage of polypeptides by the foot-and-mouth disease virus 2a peptide. J. Biol. Chem. 278(13), 11441-11448 (2003).
101. Hahn H, Palmenberg AC: Deletion mapping of the encephalomyocarditis virus primary cleavage site. J. Virol. 75(15), 7215-7218 (2001).
102. 6-methylguanine-DNA-methyltransferase and hoxb4. Mol. Ther. 10(5), 862-873 (2004).
103. Szymczak AL, Workman CJ, Wang Y et al.: Correction of multi-gene defciency in vivo using a single 'self-cleaving' 2a peptide-based retroviral vector. Nat. Biotechnol. 22(5), 589-594 (2004).
104. De Felipe P, Martin V, Cortes ML, Ryan M, Izquierdo M: Use of the 2a sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy. Gene Ther. 6(2), 198-208 (1999).
105. Carey BW, Markoulaki S, Hanna J et al.: Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc. Natl Acad. Sci. USA 106(1), 157-162 (2009).
106. Chang CW, Lai YS, Pawlik KM et al.: Polycistronic lentiviral vector for "hit and run" reprogramming of adult skin fbroblasts to induced pluripotent stem cells. Stem Cells 27(5), 1042-1049 (2009).
107. Shao L, Feng W, Sun Y et al.: Generation of IPS cells using defned factors linked via the self-cleaving 2a sequences in a single open reading frame. Cell Res 19(3), 296-306 (2009).
108. Schambach A, Baum C: Clinical application of lentiviral vectors - concepts and practice. Curr. Gene Ther. 8(6), 474-482 (2008).
109. Friedmann T, Roblin R: Gene therapy for human genetic disease? Science 175(25), 949-955 (1972).
110. Bordignon C, Notarangelo LD, Nobili N et al.: Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodefcient patients. Science 270(5235), 470-475 (1995).
111. Kohn DB, Weinberg KI, Nolta JA et al.: Engraftment of gene-modifed umbilical cord blood cells in neonates with adenosine deaminase defciency. Nat. Med. 1(10), 1017-1023 (1995).
112. Aiuti A, Slavin S, Aker M et al.: Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296(5577), 2410-2413 (2002).
113. Cavazzana-Calvo M, Hacein-Bey S, De Saint Basile G et al.: Gene therapy of human severe combined immunodefciency (SCID)-×1 disease. Science 288(5466), 669-672 (2000). (Pubitemid 30241569)
114. Sokolic R, Kesserwan C, Candotti F: Recent advances in gene therapy for severe congenital immunodefciency diseases. Curr. Opin. Hematol. 15(4), 375-380 (2008).
115. Gaspar HB, Parsley KL, Howe S et al.: Gene therapy of X-linked severe combined immunodefciency by use of a pseudotyped /retroviral vector. Lancet 364(9452), 2181-2187 (2004).
116. Qasim W, Gaspar HB, Thrasher AJ: Progress and prospects: gene therapy for inherited immunodefciencies. Gene Ther. 16(11), 1285-1291 (2009).
117. Hacein-Bey-Abina S, Garrigue A, Wang GP et al.: Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118(9), 3132-3142 (2008).
118. Howe SJ, Mansour MR, Schwarzwaelder K et al.: Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118(9), 3143-3150 (2008).
119. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100(1), 57-70 (2000).
120. Aiuti A, Cassani B, Andolf G et al.: Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy J. Clin. Invest. 117(8), 2233-2240 (2007).
121. Ott MG, Schmidt M, Schwarzwaelder K et al.: Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12(4), 401-409 (2006).
122. Stocking C, Bergholz U, Friel J et al.: Distinct classes of factor-independent mutants can be isolated after retroviral mutagenesis of a human myeloid stem cell line. Growth Factors 8(3), 197-209 (1993).
123. Baum C, Fehse B: Mutagenesis by retroviral transgene insertion: risk assessment and potential alternatives. Curr. Opin. Mol. Ther. 5(5), 458-462 (2003).
124. Bozorgmehr F, Laufs S, Sellers SE et al.: No evidence of clonal dominance in primates up to four years following transplantation of multidrug resistance 1 retrovirally-transduced long-term repopulating cells. Stem Cells 25(10), 2610-2618 (2007).
125. Laufs S, Gentner B, Nagy KZ et al.: Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. Blood 101(6), 2191-2198 (2003).
126. Gabriel R, Eckenberg R, Paruzynski A et al.: Comprehensive genomic access to vector integration in clinical gene therapy. Nat. Med. 15(12), 1431-1436 (2009).
127. Schmidt M, Schwarzwaelder K, Bartholomae C et al.: High-resolution insertion-site analysis by linear amplifcation-mediated PCR (LAM-PCR). Nat. Methods 4(12), 1051-1057 (2007).
128. Schmidt M, Zickler P, Hoffmann G et al.: Polyclonal long-term repopulating stem cell clones in a primate model. Blood 100(8), 2737-2743 (2002).
129. Appelt JU, Giordano FA, Ecker M et al.: Quickmap: a public tool for large-scale gene therapy vector insertion site mapping and analysis. Gene Ther. 16(7), 885-893 (2009).
130. Laufs S, Guenechea G, Gonzalez-Murillo A et al.: Lentiviral vector integration sites in human NOD/SCID repopulating cells. J. Gene Med. 8(10), 1197-1207 (2006).
131. Laufs S, Nagy KZ, Giordano FA, Hotz-Wagenblatt A, Zeller WJ, Fruehauf S: Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns. Mol. Ther. 10(5), 874-881 (2004).
132. Wu X, Li Y, Crise B, Burgess SM: Transcription start regions in the human genome are favored targets for MLV integration. Science 300 (5626), 1749-1751 (2003).
133. Deichmann A, Hacein-Bey-Abina S, Schmidt M et al.: Vector integration is nonrandom and clustered and infuences the fate of lymphopoiesis in SCID-X1 gene therapy J. Clin. Invest. 117(8), 2225-2232 (2007).
134. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F: HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110(4), 521-529 (2002).
135. Montini E, Cesana D, Schmidt M et al.: Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24(6), 687-696 (2006).
136. Montini E, Cesana D, Schmidt M et al.: The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest. 119(4), 964-975 (2009).
137. Naumann N, De Ravin SS, Choi U et al.: Simian immunodefciency virus lentivector corrects human X-linked chronic granulomatous disease in the NOD/SCID mouse xenograft. Gene Ther. 14(21), 1513-1524 (2007).
138. Boztug K, Dewey RA, Klein C: Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr. Opin. Mol. Ther. 8(5), 390-395 (2006).
139. Aiuti A, Roncarolo MG: Ten years of gene therapy for primary immune defciencies. Hematology Am. Soc. Hematol. Educ. Program 682-689 (2009).
140. Cartier N, Hacein-Bey-Abina S, Bartholomae CC et al.: Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326(5954), 818-823 (2009).
141. Bank A: On the road to gene therapy for b-thalassemia and sickle cell anemia. Pediatr. Hematol. Oncol. 25(1), 1-4 (2008).
142. The News Staff: Breakthrough of the Year. The Runners-Up. Science 314(5807) 1600-1607 (2009).
143. Kohn DB, Candotti F: Gene therapy fulflling its promise. N. Engl. J. Med. 360(5), 518-521 (2009).
144. Lentivirus Gene Engineering Protocols. Federico M (Ed.), Springer, USA (2010).
145. Ellis J: Silencing and variegation of gretrovirus and lentivirus vectors. Hum. Gene Ther. 16(11), 1241-1246 (2005).
146. Ailles L, Schmidt M, Santoni de Sio FR et al.: Molecular evidence of lentiviral vector-mediated gene transfer into human self-renewing, multi-potent, long-term NOD/ SCID repopulating hematopoietic cells. Mol. Ther. 6(5), 615-626 (2002).
147. Hamaguchi I, Woods NB, Panagopoulos I et al.: Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro. J. Virol. 74(22), 10778-10784 (2000).
148. Woods NB, Muessig A, Schmidt M et al.: Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood 101(4), 1284-1289 (2003).
149. Hawley RG: Progress toward vector design for hematopoietic stem cell gene therapy. Curr. Gene Ther. 1(1), 1-17 (2001).
150. Hawley RG, Lieu FH, Fong AZ, Hawley TS: Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1(2), 136-138 (1994).
151. Niwa H, Yamamura K, Miyazaki J: Effcient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108(2), 193-199 (1991).
152. Zhang F, Thornhill SI, Howe SJ et al.: Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood 110(5), 1448-1457 (2007).
153. Zychlinski D, Schambach A, Modlich U et al.: Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. 16(4), 718-725 (2008).
154. Chung JH, Bell AC, Felsenfeld G: Characterization of the chicken p-globin insulator. Proc. Natl Acad. Sci. USA 94(2), 575-580 (1997).
155. Bell AC, West AG, Felsenfeld G: The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell 98(3), 387-396 (1999).
156. Parelho V, Hadjur S, Spivakov M et al.: Cohesins functionally associate with CTCF on mammalian chromosome arms. Cell 132(3), 422-433 (2008).
157. Aker M, Tubb J, Groth AC et al.: Extended core sequences from the CHS4 insulator are necessary for protecting retroviral vectors from silencing position effects. Hum. Gene Ther. 18(4), 333-343 (2007).
158. Ma Y, Ramezani A, Lewis R, Hawley RG, Thomson JA: High-level sustained transgene expression in human embryonic stem cells using lentiviral vectors. Stem Cells 21(1), 111-117 (2003).
159. Ramezani A, Hawley TS, Hawley RG: Performance- and safety-enhanced lentiviral vectors containing the human interferon-b scaffold attachment region and the chicken b-globin insulator. Blood 101(12), 4717-4724 (2003).
160. Boulikas T: Nature of DNA sequences at the attachment regions of genes to the nuclear matrix. J. Chem. Biochem. 52(1), 14-22 (1993).
161. Auten J, Agarwal M, Chen J, Sutton R, Plavec I: Effect of scaffold attachment region on transgene expression in retrovirus vector-transduced primary T cells and macrophages. Hum. Gene Ther. 10(8), 1389-1399 (1999).
162. Agarwal M, Austin TW, Morel F, Chen J, Bohnlein E, Plavec I: Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells. J. Virol. 72(5), 3720-3728 (1998).
163. Ramezani A, Hawley TS, Hawley RG: Reducing the genotoxic potential of retroviral vectors. Methods Mol. Biol. 434, 183-203 (2008).
164. Wanisch K, Yanez-Munoz RJ: Integration-defcient lentiviral vectors: a slow coming of age. Mol. Ther. 17(8), 1316-1332 (2009).
165. Sarkis C, Philippe S, Mallet J, Serguera C: Non-integrating lentiviral vectors. Curr. Gene Ther. 8(6), 430-437 (2008).
166. Moens U, Van Ghelue M, Johannessen M: Oncogenic potentials of the human polyomavirus regulatory proteins. Cell Mol. Life Sci. 64(13), 1656-1678 (2007).
167. Humme S, Reisbach G, Feederle R et al.: The ebv nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc. Natl Acad. Sci. USA 100(19), 10989-10994 (2003).
168. Nightingale SJ, Hollis R P, Pepper KA et al.: Transient gene expression by nonintegrating lentiviral vectors. Mol. Ther. 13(6), 1121-1132 (2006).
169. Cornu TI, Cathomen T: Targeted genome modifcations using integrase-defcient lentiviral vectors. Mol. Ther. 15(12), 2107-2113 (2007).
170. Lombardo A, Genovese P, Beausejour CM et al.: Gene editing in human stem cells using zinc fnger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 25(11), 1298-1306 (2007).
171. Urnov FD, Miller JC, Lee YL et al.: Highly effcient endogenous human gene correction using designed zinc-fnger nucleases. Nature 435(7042), 646-651 (2005).
172. Ciceri F, Bonini C, Stanghellini MT et al.: Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the tk007 trial): a non-randomised Phase I-II study. Lancet Oncol. 10(5), 489-500 (2009).